Characteristics of the cohort
| Whole cohort (N=148) | |
| Age at study entry (mean±SD) | 42.2±12.5 |
| Disease duration at study entry (mean±SD) at study entry | 13.9±9.2 |
| Cumulative organ involvement | |
| Musculoskeletal involvement (ever) | 76.3% |
| Haematological involvement (ever) | 57.5% |
| Skin involvement (ever) | 56.1% |
| Kidney involvement (ever) | 53.3% |
| Serositis (ever) | 21.6% |
| Neuropspychiatric involvement (ever) | 12.8% |
| Constitutional symptoms: fever and weight loss (ever) | 6.8% |
| Ongoing therapies | |
| Hydroxychloroquine | 76.3% |
| Traditional immunosuppressants | 36.5% |
| Azathioprine | 10.4% |
| Mycophenolate | 15.0% |
| Metotrexate | 4.8% |
| Cyclosporine | 2% |
| Tacrolymus | 4.9% |
| Biological drugs | 12.9% |
| SLICC/DI at study entry (median (IQR)) | 0 (0–1) |
| SLICC/DI at last observation (median (IQR)) | 0 (0–2) |